The obesity epidemic is still bursting at the seams.
At the moment, 1.9 billion people are overweight, with more than 650 million considered obese. In addition, by 2022, $245 billion will be spent on products and services battling the issue.
All according to NeonMind Biosciences (CSE:NEON) (OTC:NMDBF), which is one of two companies working to develop psilocybin into a prescription drug for weight management.
After all, psilocybin activates serotonin receptors, or “nature’s own appetite suppressant,” says Psychology Today. “This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.” In short, we could be looking at a massive game-changer for a multi-billion-dollar weight management market.